Apremilast

featured

WARNING: This product is for research use only, not for human or veterinary use.

Description:Apremilast, also known as CC-10004, is a thalidomide analog and is an orally available small molecule inhibitor of phosphodiesterase 4 (PDE4). Apremilast specifically inhibits PDE4 and inhibits spontaneous production of TNF-alpha from human rheumatoid synovial cells. It has anti-inflammatory activity. Apremilast was approved by the USFDA in March 2014 for treatment of adults with active psoriatic arthritis. It is also being tested for its efficacy in treating other chronic inflammatory diseases such as ankylosing spondylitis, Behcet's disease, and rheumatoid arthritis.

Price and Availability

Apremilast, purity > 98%, is in stock. The same day shipping out after order is received.

Synonym:CC10004; CC-10004; CC 10004; Apremilast; brand name: Otezla.

IUPAC/Chemical Name:(S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide

InChi Key:IMOZEMNVLZVGJZ-QGZVFWFLSA-N

InChi Code:InChI=1S/C22H24N2O7S/c1-5-31-19-11-14(9-10-18(19)30-3)17(12-32(4,28)29)24-21(26)15-7-6-8-16(23-13(2)25)20(15)22(24)27/h6-11,17H,5,12H2,1-4H3,(H,23,25)/t17-/m1/s1

SMILES Code:CC(NC1=CC=CC(C(N2[C@@H](C3=CC=C(OC)C(OCC)=C3)CS(=O)(C)=O)=O)=C1C2=O)=O

Technical Data

References

1: Thompson BJ, Furniss M, Zhao W, Chakraborty B,Mackay-Wiggan J. An Oral Phosphodiesterase Inhibitor (Apremilast) forInflammatory Rosacea in Adults: A Pilot Study. JAMA Dermatol. 2014 Jul23. doi: 10.1001/jamadermatol.2013.10526. [Epub ahead of print] PubMedPMID: 25054629.

2: Liu Y, Zhou S, Wan Y, Wu A, Palmisano M. The impact ofco-administration of ketoconazole and rifampin on the pharmacokineticsof apremilast in healthy volunteers. Br J Clin Pharmacol. 2014 Jun 24.doi: 10.1111/bcp.12448. [Epub ahead of print] PubMed PMID: 24962564.

3: Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF, Man HW,Muller GW, Stirling DI, Chopra R. Apremilast is a selective PDE4inhibitor with regulatory effects on innate immunity. Cell Signal. 2014Sep;26(9):2016-29. doi: 10.1016/j.cellsig.2014.05.014. Epub 2014 May 29.PubMed PMID: 24882690.

4: Apremilast (Otezla) for psoriatic arthritis. Med Lett Drugs Ther.2014 May 26;56(1443):41-2. PubMed PMID: 24869713.

5: FitzGerald O. Spondyloarthropathies: Apremilast: welcome advance intreatment of psoriatic arthritis. Nat Rev Rheumatol. 2014Jul;10(7):385-6. doi: 10.1038/nrrheum.2014.77. Epub 2014 May 20. PubMedPMID: 24846499.

6: Poole RM, Ballantyne AD. Apremilast: first global approval. Drugs.2014 May;74(7):825-37. doi: 10.1007/s40265-014-0218-4. PubMed PMID:24797159.

7: Varada S, Tintle SJ, Gottlieb AB. Apremilast for the treatment ofpsoriatic arthritis. Expert Rev Clin Pharmacol. 2014 May;7(3):239-50.doi: 10.1586/17512433.2014.904200. Epub 2014 Apr 4. PubMed PMID:24702658.

8: Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J,Gladman DD, Lespessailles E, Hall S, Hochfeld M, Hu C, Hough D, StevensRM, Schett G. Treatment of psoriatic arthritis in a phase 3 randomised,placebo-controlled trial with apremilast, an oral phosphodiesterase 4inhibitor. Ann Rheum Dis. 2014 Jun;73(6):1020-6. doi:10.1136/annrheumdis-2013-205056. Epub 2014 Mar 4. PubMed PMID: 24595547;PubMed Central PMCID: PMC4033106.

9: Gottlieb AB, Matheson RT, Menter A, Leonardi CL, Day RM, Hu C,Schafer PH, Krueger JG. Efficacy, tolerability, and pharmacodynamics ofapremilast in recalcitrant plaque psoriasis: a phase II open-labelstudy. J Drugs Dermatol. 2013 Aug;12(8):888-97. PubMed PMID: 23986162.

10: Schafer PH, Day RM. Novel systemic drugs for psoriasis: mechanism ofaction for apremilast, a specific inhibitor of PDE4. J Am Acad Dermatol.2013 Jun;68(6):1041-2. doi: 10.1016/j.jaad.2012.10.064. PubMed PMID:23680197.

我国旅美科学家陈清奇博士创立的MedKoo美帝药库医药公司目前正在建立全球第一个小分子抗癌药库。 MedKoo是一家以研发、生产和销售小分子抗癌化合物为主的医药科技公司。 业务范围 为全球所有从事抗癌药物研究和开发的制药公司，高校，研究院所，政府相关机构提供与抗癌药物分子相关的产品、试剂和技术服务。 技术核心 以药物化学合成技术为核心，密切结合全球抗癌新药研发领域中的新技术、新理论、新趋势和新的发展方向，不断推出抗癌化合物新品种。 建造目标 MedKoo美帝药库的目标是：建成全球最大的小分子抗癌药库 ，品种最多最全、质量最好最可靠。美帝药库的宗旨是：客户第一；质量第一；信誉第一；创新第一。